Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mika Hoshino is active.

Publication


Featured researches published by Mika Hoshino.


Journal of Hepato-biliary-pancreatic Sciences | 2012

Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients

Hisahito Endo; Takuro Saito; Akira Kenjo; Mika Hoshino; Masanori Terashima; Tetsu Sato; Takayuki Anazawa; Takashi Kimura; Takao Tsuchiya; Atsushi Irisawa; Hiromasa Ohira; Takuto Hikichi; Tadayuki Takagi; Mitsukazu Gotoh

PurposeTo determine the feasibility, safety and histological change of preoperative endoscopic ultrasound-guided fine-needle injection (PEU-FNI) of immature DCs (iDCs) with OK-432 in pancreatic cancer patients.MethodsNine patients enrolled in the trial (DC group) and were compared with 15 patients operated on without iDC injection (non-DC group). Adverse events of PEU-FNI and postoperative complications were evaluated according to CTC-AE ver.3.0 and the Clavien–Dindo classification/ISGPF definition, respectively. Histological changes within the tumor and lymph nodes were evaluated by immunohistochemical examination of infiltrating inflammatory cells (CD4+, CD8+, Foxp3+ and CD83+).ResultsThere were no severe toxicities following PEU-FNI, except for one transient grade 3 fever, and there were no significant differences in the incidence of postoperative complications between the two groups. Colliquative necrosis and diffusely scattered TUNEL-positive cells were observed at the injection sites. CD83+ cells significantly accumulated in the regional lymph nodes of the DC group as well as Foxp3+ cells in the regional and distant lymph nodes. The two DC group patients, one of which was stage IV with distant lymph node metastasis, survived more than 5 years without requiring adjuvant theraphy.ConclusionPEU-FNI was feasible and safe, and further study needs to confirm and enhance antitumor responses.


Journal of Oncology | 2015

Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma

Jun Osugi; Yuka Kimura; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Athushi Yonechi; Mika Hoshino; Mitsunori Higuchi; Yutaka Shio; Hiroyuki Suzuki; Mitsukazu Gotoh

Objective. The aim of this study was to investigate the prognostic value of MicroRNA-210 (miR-210) expression in patients with non-small-cell lung cancer (NSCLC). Methods. We examined the miR-210 expression of samples of 80 patients, who underwent surgical resection at Fukushima Medical University from 2004 to 2007, by using quantitative RT-PCR. The relationship between miR-210 expression and clinicopathological factors as well as histological subtype was statistically analyzed. Results. miR-210 expression showed an inverse correlation with disease-free and overall survival in patients with NSCLC. Significant correlations were found between miR-210 expression and lymph node metastasis, late disease stages, and poor prognosis in patients with adenocarcinoma. Multivariate Cox analysis indicated that miR-210 expression was an independent prognostic factor for disease-free survival in patients with adenocarcinoma. Conclusions. We showed that miR-210 may be a prognostic biomarker for patients with NSCLC, especially for those with lung adenocarcinoma.


Lung Cancer | 2015

Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer

Jun Osugi; Takumi Yamaura; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Mika Hoshino; M. Higuchi; Hiroyuki Suzuki; Mitsukazu Gotoh

OBJECTIVE Metabolic alternations are deemed a hallmark of cancer cells. Among many metabolic pathways, glycolysis and lipogenesis are essential metabolic processes in cancer cells. In this study, we examined the prognostic impact of the combined expression of glycolysis-related glucose transporter 1 (GLUT1) and ATP-citrate lyase (ACLY), which are important molecules in lipogenesis, in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS GLUT1 and ACLY expression in 134 NSCLC specimens were determined by immunohistochemistry using a tissue microarray (TMA). We examined the overall survival of patients with GLUT1-, ACLY- or GLUT+ACLY-positive expression using Kaplan-Meier analysis. We analyzed the prognostic impact of combined GLUT1 and ACLY expression according to lymph node status using multivariate Cox analysis. RESULTS Patients with GLUT1- or ACLY-positive expression exhibited poorer overall survival compared with GLUT1- or ACLY-negative patients. GLUT1-positive/ACLY-positive expression status was associated with the worst overall survival, in contrast with GLUT1 negative/ACLY-negative expression status, which was correlated with the best overall survival (P=0.003). GLUT1-positive/ACLY-positive expression was significantly correlated with poor prognosis in node-negative but not in node-positive patients. Multivariate Cox analysis indicated combined expression of GLUT1 and ACLY was an independent prognostic factor for overall survival in node-negative patients with NSCLC (P=0.049). CONCLUSION These results suggest that the combined expression of GLUT1 and ACLY could be a more valuable prognostic factor than their individual expression in node-negative patients with NSCLC.


International Journal of Oncology | 2015

Clinical significance of expanded Foxp3+ Helios- regulatory T cells in patients with non-small cell lung cancer

Satoshi Muto; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Osugi; Mika Hoshino; Mitsunori Higuchi; Hiroyuki Suzuki; Mitsukazu Gotoh

The functions of different regulatory T cell (Treg) types in cancer progression are unclear. Recently, expression of the transcription factor Helios was proposed as a marker for natural (non-induced) Tregs. The present study investigated the clinical significance of Helios expression in patients with non-small cell lung cancer (NSCLC). We enrolled 64 patients with NSCLC, of whom 45 were treated surgically and 19 received chemotherapy because of advanced/recurrent disease. Their peripheral blood mononuclear cells were examined by flow cytometry. From the 45 surgery patients, we matched 9 patients with recurrent disease with 9 stage-matched patients without recurrence (n=18), compared their specimens immunohistochemically for tumor infiltrating lymphocytes (TILs) and analyzed these data against clinicopathological factors. Helios expression in Foxp3+ Tregs was 47.5±13.3% in peripheral blood and 18.1±13.4% in tumor specimens. Percentage of Helios− Tregs among CD4+ T cells were significantly higher in the cancer patients (2.4%), especially those with stage IA disease (2.6%) than in healthy donors (1.5%; P<0.001). Patients with low levels of Helios expression in Tregs among their TILs had significantly poorer survival (P=0.038). Helios− Tregs may affect immune suppression, even in early stage NSCLC; they could also be a useful prognostic biomarker in patients with NSCLC, and possibly a novel cancer immunotherapy target.


Human Vaccines & Immunotherapeutics | 2014

Recent advances in immunotherapy for non-small-cell lung cancer

Hiroyuki Suzuki; Yuki Owada; Yuzuru Watanabe; Takuya Inoue; Mitsuro Fukuharav; Takumi Yamaura; Satoshi Mutoh; Naoyuki Okabe; Hiroshi Yaginuma; Takeo Hasegawa; Atsushi Yonechi; Jun Ohsugi; Mika Hoshino; Mitsunori Higuchi; Yutaka Shio; Mitsukazu Gotoh

Despite of recent development in the field of molecular targeted therapies, lung cancer is a leading cause of cancer death in the world. Remarkable progress has been made recently in immunotherapy for patients with non-small-cell lung cancer (NSCLC), with several modalities, concepts, and treatment settings being investigated. In vaccine development, large-scale clinical trials such as those with L-BLP25, belagenpumatucel-L, TG4010, and talactoferrin are already ongoing and some results have been reported. A trial of a vaccine as adjuvant therapy for patients with completely resected NSCLC is also ongoing with one of the major cancer-testis antigens, melanoma-associated antigen (MAGE)-A3. More recently, the effectiveness of multiple peptide vaccines has also been shown. Recently developed unique treatment modalities are the immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, which also show promise. However, although therapeutic cancer vaccines are generally thought to be safe, severe adverse events should be monitored carefully when using immune checkpoint inhibitors. Here, we discuss recent advances and future perspectives of immunotherapy for patients with NSCLC.


Interactive Cardiovascular and Thoracic Surgery | 2016

Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis

Yuki Matsumura; Yuki Owada; Takumi Yamaura; Satoshi Muto; Jun Osugi; Mika Hoshino; Mitsunori Higuchi; Tetsuya Ohira; Hiroyuki Suzuki; Mitsukazu Gotoh

OBJECTIVES Epidermal growth factor receptor (EGFR) mutation is a robust prognostic factor in patients with lung adenocarcinoma (ADC). However, the role of EGFR mutation status as a recurrence-risk factor remains unknown because the presence of such mutations is associated with other background characteristics. We therefore conducted a matched-pair analysis to compare recurrence-free survival (RFS) in matched cohorts of patients with lung ADC. METHODS We enrolled 379 patients who underwent surgical resection for lung ADC between 2005 and 2012. We determined the EGFR mutation status of each tumour. Matching their age, gender, smoking history and pathological stage (pStage), we compared RFS between matched cohorts with and without EGFR mutation (n = 86 each). RESULTS The median age was 67 years, there were 39 (45%) men, 39 (45%) ex- or current smokers and pStage I: 71 (83%), II: 5 (6%), III: 8 (9%), IV: 2 (2%) in each group. The 3- and 5-year RFS rates in patients with mutant and wild-type EGFR were 85 and 78%, and 74 and 60%, respectively, with significant differences between the groups (P = 0.040). Multivariate analysis identified vascular invasion and lymphatic permeation, but not EGFR mutation status, as independent risk factors for recurrence. CONCLUSIONS EGFR-gene mutation might be a favourable recurrence-risk factor in patients with surgically resected lung ADC, but further studies in larger cohorts are needed to verify this hypothesis.


Oncology Letters | 2017

Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons

Mitsunori Higuchi; Hironori Takagi; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Atsushi Yonechi; Jun Osugi; Mika Hoshino; Yutaka Shio; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Hiroyuki Suzuki; Mitsukazu Gotoh

The present retrospective multi-center study aimed to evaluate the efficacy and feasibility of nanoparticle albumin-bound (nab)-paclitaxel plus carboplatin as a second or late-phase chemotherapy in patients with non-small cell lung cancer (NSCLC). A total of 25 patients with recurrent or advanced NSCLC who had received previous chemotherapy were treated with nab-paclitaxel (70-100 mg/m2, intravenously) on days 1, 8 and 15 every 28 days with a carboplatin area under the concentration-time curve of 4-6 on day 1. The overall response rate, disease control rate, progression-free survival (PFS), overall survival (OS) and toxicities were statistically evaluated. Of the 25 patients, there were 9 cases of recurrent disease following surgery, 16 cases of advanced disease, 13 cases of adenocarcinoma, 11 cases of squamous cell carcinoma and 1 case of large cell carcinoma. A total of 13 patients received second-line chemotherapy and 12 received fourth-line or later chemotherapy. One patient exhibited a complete response, 7 had a partial response, 10 exhibited stable disease and 7 had progressive disease. The overall response rate was 32.0% and the disease control rate was 72.0%. The median PFS and median OS following nab-paclitaxel treatment were 4.0 and 14.0 months, respectively. Frequent treatment-associated adverse events were myelosuppression, peripheral neuropathy, gastrointestinal symptoms and baldness, the majority of which were grade 1-2. Grade 3-4 neutropenia, thrombocytopenia and anemia occurred in 7 (28.0%), 3 (12.0%) and 2 (8.0%) patients, respectively. No patients experienced grade 3-4 sensory neuropathy and no grade 5 adverse effects were observed. Nab-paclitaxel plus carboplatin as second-phase or later chemotherapy provided a small but significant survival benefit for patients with recurrent or advanced NSCLC, with tolerable adverse effects. To the best of our knowledge, the results of the present study demonstrated for the first time that nab-paclitaxel plus carboplatin is a promising and feasible late-phase chemotherapeutic agent for NSCLC.


Journal of Thoracic Oncology | 2018

Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report

Yuki Owada-Ozaki; Satoshi Muto; Hironori Takagi; Takuya Inoue; Yuzuru Watanabe; Mitsuro Fukuhara; Takumi Yamaura; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Ohsugi; Mika Hoshino; Yutaka Shio; Hideaki Nanamiya; Jun-ichi Imai; Takao Isogai; Shinya Watanabe; Hiroyuki Suzuki

Introduction: Tumor mutation burden (TMB) is thought to be associated with the amount of neoantigen in the tumor and to have an important role in predicting the effect of immune checkpoint inhibitors. However, the relevance of TMB to prognosis is not yet fully understood. In this study, we investigated the clinical significance of TMB in patients with NSCLC and examined the relationship between TMB and prognosis. Methods: We calculated TMB within individual tumors by whole‐exome sequencing analysis using next‐generation sequencing. We included that there were 90 patients with NSCLC who underwent surgery in the Hospital of Fukushima Medical University from 2013 to 2016. No patients received chemotherapy or immunotherapy before surgery. We assessed the correlation between TMB and prognosis. Results: TMB greater than 62 was associated with worse overall survival (OS) of patients with NSCLC (hazard ratio [HR] = 6.633, p = 0.0003). Multivariate analysis showed poor prognosis with high TMB (HR = 12.31, p = 0.019). In patients with stage I NSCLC, higher TMB was associated with worse prognosis for both OS (HR = 7.582, p = 0.0018) and disease‐free survival (HR = 6.07, p = 0.0072). Conclusions: High TMB in NSCLC is a poor prognostic factor. If high TMB is a predictor of the efficacy of immune checkpoint inhibitors, postoperative adjuvant therapy with immune checkpoint inhibitors may contribute to improvement of recurrence and OS.


Interactive Cardiovascular and Thoracic Surgery | 2017

Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma

Yuki Matsumura; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Takeo Hasegawa; Mika Hoshino; Jun Osugi; Mitsunori Higuchi; Hiroyuki Suzuki

OBJECTIVES The purpose of this analysis was to examine the relationship between epidermal growth factor receptor (EGFR) mutation status and clinicopathological factors in a cohort of patients who underwent surgical resections for lung adenocarcinoma. METHODS From the patients who underwent surgical resections for primary lung cancers between 2005 and 2012, 371 consecutive adenocarcinoma patients were enrolled in this study, and their tumours were analysed for EGFR mutations. We examined the clinicopathological factors of all enrolled patients, including age, sex, pathological stage and smoking status and tested for associations with EGFR mutation status. RESULTS Among the 371 enrolled patients, 195 (52%) patients had EGFR mutations. There were significantly more women, never smokers and tumours of lower grade histology in the EGFR mutation group than in the wild-type group (P < 0.001 each). However, other factors, such as pathological stage and World Health Organization classification, were not significantly associated with mutation status. Multivariable analysis showed that age, smoking history and histological grade were independently associated with EGFR mutations (P = 0.026, P < 0.001 and P < 0.001, respectively), but sex was not. Regarding smoking status, especially, frequency of EGFR mutation decreased, as smoking index increased. On the other hand, sex and smoking cessation (whether the patients were former or current smokers) were not significantly associated with EGFR mutation status. CONCLUSIONS In our cohort of patients who underwent surgical resection for lung adenocarcinoma, EGFR mutation status was strongly associated with smoking status, especially smoking index.


Fukushima journal of medical science | 2018

Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancer

Mitsunori Higuchi; Hironori Takagi; Yuki Ozaki; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Osugi; Mika Hoshino; Yutaka Shio; Hiroyuki Suzuki

BACKGROUND According to previous reports, lobectomy with bronchoplasty or angioplasty is a more feasible surgery than pneumonectomy for central-type non-small cell lung cancer. However, few studies have compared both the short- and long-term outcomes between pneumonectomy and pulmonary function-preserving surgery. METHODS From January 2004 to December 2015, 18 patients underwent pneumonectomy (Group PN) and 12 patients underwent pulmonary function-preserving surgery (group PS) at Fukushima Medical University Hospital. Clinicopathological factors were statistically compared between the two groups. RESULTS The operation times in Group PN and Group PS were 285.9±27.9 and 271.3±99.2 min, respectively (p=0.613), while the amounts of intraoperative bleeding were 324.8±248.9 and 164.5±116.6 g, respectively (p=0.020). The duration of chest drainage and hospitalization after surgery in both groups were not significantly different but there was a tendency toward shorter periods of these durations in Group PS. The 5-year disease-free survival (DFS) rate in Group PN and PS was 51.4% and 74.1%, respectively, without a significant difference (p=0.298). The 5-year overall survival (OS) rate in Group PN and PS was 52.5% and 56.6%, respectively, also without a significant difference (p=0.748). The 5-year OS rate was inferior to the 5-year DFS rate in Group PS, and the 5-year OS rate was not better than the 5-year DFS rate in Group PN. CONCLUSIONS The short-term results were better in Group PS than PN. However, the long-term results in both groups were similar. Other causes of death influenced OS in both groups; this result might have been affected by the surgical procedures.

Collaboration


Dive into the Mika Hoshino's collaboration.

Top Co-Authors

Avatar

Hiroyuki Suzuki

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Takeo Hasegawa

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Mitsukazu Gotoh

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Mitsunori Higuchi

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Jun Osugi

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Yutaka Shio

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Takumi Yamaura

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Naoyuki Okabe

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Satoshi Muto

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Yuki Matsumura

Fukushima Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge